Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro
Open Access
- 6 January 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 117 (1), 290-298
- https://doi.org/10.1182/blood-2010-08-300756
Abstract
Inhibitory antibodies to factors VIII or IX represent a serious complication for hemophilia patients. Treatment involves products that bypass the intrinsic pathway and promote thrombin generation. Direct infusion of factor Xa should also restore hemostasis; however, it has a short half-life in plasma and could activate systemic coagulation in an uncontrolled fashion. Here we show that factor Xa mutants with zymogen-like properties (FXaI16L and FXaV17A) circumvent these limitations. In the absence of factor Va, the FXa variants are poor enzymes for a range of physiological ligands and are resistant to inactivation by antithrombin III and tissue factor pathway inhibitor. Notably, assembly of FXaI16L and FXaV17A on activated platelets with factor Va to form prothrombinase completely restores biologic activity. In hemophilic plasma, FXaI16L and FXaV17A have prolonged half-lives compared with wild-type factor Xa (approximately 60 minutes vs approximately 1 minute) and promote robust thrombin generation that bypasses the intrinsic pathway. The variants require factor Va generated in situ for procoagulant function, and cofactor inactivation by the protein C pathway regulates their activity. The efficacy, extended half-life, and mechanism of action suggest that novel zymogen-like forms of factor Xa might prove useful as new therapeutic procoagulants to treat deficiencies upstream of the common pathway.Keywords
This publication has 51 references indexed in Scilit:
- Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitorsHaemophilia, 2009
- The Conformational Switch from the Factor X Zymogen to Protease State Mediates Exosite Expression and Prothrombinase AssemblyJournal of Biological Chemistry, 2008
- Mechanism of action, development and clinical experience of recombinant FVIIaJournal of Biotechnology, 2006
- FEIBA®: mode of actionHaemophilia, 2004
- Removal of B-domain Sequences from Factor V Rather than Specific Proteolysis Underlies the Mechanism by Which Cofactor Function Is RealizedPublished by Elsevier BV ,2004
- Prothrombinase Assembly and S1 Site Occupation Restore the Catalytic Activity of FXa Impaired by Mutation at the Sodium-binding SiteJournal of Biological Chemistry, 2002
- Kinetics of Human Factor VII ActivationBiochemistry, 1996
- A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivoBritish Journal of Haematology, 1988
- Inhibition of prothrombinase complex by plasma proteinase inhibitorsBiochemistry, 1984
- Solution composition dependent variation in extinction coefficients for p-NitroanilineBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1983